Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers

Archives of Gynecology and Obstetrics

Volumn 284, Issue 6, 2011, Pages 1515-1521

  Hasegawa, Kiyoshi ^a   Torii, Yutaka ^a   Ishii, Risa ^a   Oe, Shuko ^a   Kato, Rina ^a   Udagawa, Yasuhiro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell cycle regulator proteins; COX 2; COX 2 inhibitor; Endometrial cancer; Immunohistochemistry

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; CELL CYCLE PROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOTIC INDEX; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; NICK END LABELING; ONCOLOGICAL PARAMETERS; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; STOMACH DISCOMFORT; APOPTOSIS; CASE CONTROL STUDY; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; APOPTOSIS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOMETRIAL NEOPLASMS; ETODOLAC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

EID: 84862632817     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-011-1883-0     Document Type: Article

References (36)

1. Uefuji K, Ichikura T, Shinomiya N, Mochizuki H (2000) Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res 20:4279-4284 (Pubitemid 32141773)
2. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induced apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60:5767-5772
3. Li M, Lotan R, Levin B, Tahara E, Lippman SM, Xu XC (2000) Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 9:545-549 (Pubitemid 30396174)
4. Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M et al (2001) Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 30:41-47 (Pubitemid 32044879)
5. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeff SK et al (2000) Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitors, NS-398. Cancer Res 60:4926-4931
6. Tsubouchi Y, Mukai S, Kawahito Y, Yamada R, Kohno M, Inoue K et al (2000) Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 20:2867-2872
7. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356-4362 (Pubitemid 29418754)
8. Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y et al (2005) Expression of cyclooxygenase-2 (COX-2) in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 26:1419-1428
9. Uotila PJ, Erkkola RU, Klemi PJ (2002) The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann Med 34:428-433 (Pubitemid 36026774)
10. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K (2002) Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 33:213-219 (Pubitemid 34298737)
11. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, Dubois RN et al (2000) Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2:483-490 (Pubitemid 32098682)
12. Farrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A et al (2002) Cyclooxygenase-2 expression in endometrial carcinoma-correlation with clinicopathological parameter and clinical outcome. Cancer 95:801-807 (Pubitemid 34839672)
13. Jeon YT, Kang S, Kang DH, Yoo KY, Park IA, Bang YJ et al (2004) Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev 13:1538-1542 (Pubitemid 39202324)
14. Genç S, Attar E, Gürdöl F, Kendigelen S, Bilir A, Serdaroǧlu H (2007) The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture. Clin Exp Med 7:6-10 (Pubitemid 46475005)
15. Wood NJ, Quinton NA, Burdall S, Sheridan E, Duffy SR (2007) Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. Int J Gynecol Cancer 17:447-454 (Pubitemid 46426781)
16. Detre S, Saclani Jotti G, Dowsett M (1995) A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48:876-878
17. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA et al (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitor in an animal model of Barrett's esophagus. Gastroenterology 122:1101-1112 (Pubitemid 34267291)
18. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044
19. Oshima M, Murai (Hara) N, Kargman S, Arguello M, Luk P, Kwong P et al (2001) Chemoprevention of intestinal polyposis in the ApcΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61:1733-1740 (Pubitemid 34292612)
20. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952 (Pubitemid 30419089)
21. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP et al (2002) A randomized, double blinded, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860 (Pubitemid 34539050)
22. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al (2005) Cardiovascular events associated with refecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102 (Pubitemid 40365350)
23. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al (2005) Cardiovascular risk with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 352:1071-1080 (Pubitemid 40365348)
24. McGettigan P, Henny D (2006) Cardiovascular risk and inhibitor of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633-1644 (Pubitemid 44511610)
25. Roumie CL, Choma NN, Kaltenbach L, Mitcher EF, Arbogast PG, Griffin MR (2009) Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 18:1053-1063
26. Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA et al (2006) Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 29:621-632 (Pubitemid 44175032)
27. Warner JJ, Weideman RA, Kelly KC, Brilakis ES, Banerjee S, Cunningham F et al (2008) The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a genetic COX-2 selective inhibitor. J Cardiovasc Pharmacol Ther 13:252-260
28. Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S et al (2010) Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 126:1467-1473
29. Altorki NK, Keresztes JL, Port JL, Libby DM, Korst RJ, Flieder DB et al (2003) Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21:2645-2650 (Pubitemid 46606306)
30. Shinohara N, Kumagai A, Kanagawa K, Maruyama S, Abe T, Sazawa A, Nonomura K (2009) Multicenter phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon-α for metastatic renal cell carcinoma. Jpn J Clin Oncol 39:720-729
31. Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S (2010) Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 44:286-288
32. Aruajo AM, Mendez JC, Coelho AL, Sousa B, Barata F, Figueiredo A et al (2009) Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invasion 27:391-396
33. Debucquoy A, Roels S, Goethals L, Libbrecht L, Culsem EV, Geboes K et al (2009) Double blind randomized phase II study with radiation + 5-fluorouracil ± celecoxib for resectable rectal cancer. Radiother Oncol 93:273-278
34. Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A et al (2009) A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 29:1483-1488
35. Watanabe J, Sato H, Kanai T, Kamata Y, Jobo T, Hata H et al (2002) Paradoxical expression of cell cycle inhibitory p27 in endometrial adenocarcinoma of the uterine corpus-correlation with proliferative and clinicopathological parameters. Br J Cancer 87:81-85
36. Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J et al (2003) Immunohistochemical expression of cyclins, cyclindependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 34:471-478 (Pubitemid 36666813)